Key points from article :
Endogena Therapeutics, a biotech pioneer, gains FDA approval for clinical study of EA 2351, a revolutionary AMD treatment.
The groundbreaking EA 2351 program targets geographic atrophy (GA), a severe AMD form, with unique regenerative potential.
Matthias Steger, CEO of Endogena Therapeutics, expresses excitement for this momentous achievement, offering hope to AMD patients.
EA-2351's focus on retinal pigment epithelial (RPE) cells opens new possibilities for regenerating photoreceptor function.
This marks the company's second clinical program, following the success of EA-2353 for retinitis pigmentosa.
Endogena Therapeutics continues its mission to unlock regenerative potential, making a significant impact on patients' lives.
